Kainova Therapeutics News and Activities

Acquisition, funding and merger involving Kainova Therapeutics.

• Domain Therapeutics has changed its company name to Kainova Therapeutics (posted on February 12 2026).
• Kainova Therapeutics has just announced a $32 Million fundraising (posted on February 11 2026).

View the org chart displaying its 19 main executives

Most searched biographies at Kainova Therapeutics

• Sean Macdonald, Chief Executive Officer
• Louis-Etienne Fortier, Director
• Rosemary Mazanet, Director

Popular executive movements at Kainova Therapeutics

• Jean Marie Cuillerot has joined the company as Chief Medical Officer  (posted on November 14 2025).

Create your alert
to follow the executive moves at Kainova Therapeutics.

Kainova Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Kainova Therapeutics

• Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
• Kainova Therapeutics to Present Clinical and Preclinical Updates on its GPCR Programs at AACR Annual Meeting 2026
• Reversing tumor immunosuppression with next-gen GPCR modulation - Beyond Biotech - the podcast from Labiotech
• Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
• Kainova Therapeutics, formerly Domain Therapeutics, is a clinical-stage biopharmaceutical company driving a robust pipeline of GPCR-modulating therapies
• Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
• All
• View more press releases Close

Social media about Kainova Therapeutics

• Kainova Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kainova Therapeutics on LinkedIn, X (Twitter) & YouTube